NASDAQ:XERS

Xeris Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XERS

*Your capital is at risk

$5.89

-0.110 (-1.83%)

At Close: Jun 03, 2026

Xeris Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -36.34. In total, the insiders bought 4.12M and sold 1.83M XERS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-36.34
● Buy	4.12M shares
● Sell	1.83M shares
52% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Jan 30, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -36.34. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 13, 2025 Buy	Common Stock P-Purchase	Mcculloch Kevin See Remarks	Officer	25 000 Value: $109.5K
Jun 13, 2025 Buy	Common Stock P-Purchase	Mcculloch Kevin See Remarks	Officer	25 000 Value: $109.5K
Jun 04, 2025 Buy	Common Stock A-Award	Bormann-kennedy Barbara-jean Anne Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Persky Marla Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Halkuff Dawn Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Sherman Jeffrey W Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Johnson John Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Kong Garheng Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Kong Garheng Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Johnson John Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Sherman Jeffrey W Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Halkuff Dawn Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Persky Marla Director	Director	50 000 Value: $221.5K
Jun 04, 2025 Buy	Common Stock A-Award	Bormann-kennedy Barbara-jean Anne Director	Director	50 000 Value: $221.5K
Apr 02, 2025 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	733 Value: $4K
Apr 02, 2025 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	733 Value: $4K
Mar 28, 2025 Buy	Common Stock A-Award	Brady James Aloysius Director	Director	100 000 Value: $558.0K
Mar 28, 2025 Buy	Common Stock J-Other	Brady James Aloysius	Director	0 Value: $0
Mar 28, 2025 Buy	Common Stock J-Other	Brady James Aloysius	Director	0 Value: $0
Mar 28, 2025 Buy	Common Stock A-Award	Brady James Aloysius Director	Director	100 000 Value: $558.0K
Mar 20, 2025 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	40 000 Value: $217.2K
Mar 20, 2025 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	40 000 Value: $217.2K
Feb 25, 2025 Buy	Stock Appreciation Right	Nguyen Anh Tu See Remarks	Officer	150 000 Value: $564.0K
Feb 25, 2025 Buy	Common Stock	Nguyen Anh Tu See Remarks	Officer	0 Value: $0
Feb 25, 2025 Buy	Common Stock	Nguyen Anh Tu See Remarks	Officer	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XERIS PHARMACEUTICALS INC

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi...

Read Full Profile Here